Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cellebrite DI Ltd. (“Cellebrite” or “the Company”) (NASDAQ: CLBT). Investors who purchased Cellebrite securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Cellebrite has violated federal securities laws.

Cellebrite Investigation Details

On August 13, 2026, Cellebrite reported its financial results for the second quarter of 2026. Among other items, Cellebrite disclosed Annual Recurring Revenue (“ARR”) that missed the bottom end of its prior guidance. The Company also lowered its full-year ARR guidance and announced the abrupt replacement of CEO Tom Hogan. Following this news, Cellebrite’s stock price dropped $4.45 per share, or 29.18%, to close at $10.80 on August 13, 2026.

What’s Next for Cellebrite Investors?

If you are aware of any facts relating to this investigation or purchased Cellebrite securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911